Cancer biotech Inhibrx files for USD 75 M IPO
Celgene-partnered biotech Inhibrx aftersecuring USD 40 Million from Viking Global Investors, has filed
for USD 75 million IPO. Built on a
single-domain antibody platform, it has three oncology programs in human
clinical trials, a rare disease program, and two preclinical drugs. Inhibrx,
has also granted Italian-based Chiesi
Farmaceutici, the rights for the development and commercialization of AAT-fusion
protein INBRX-101, outside of North
America. Chiesi will pay USD 10 million upfront and buy a USD 10 million worth
of shares in Inhibrx.
EpimAb Biotherapeutics raises USD 74 M to accelerate bispecific pipeline
EpimAb Biotherapeutics, a Shanghai-based biopharmaceutical company specializing in bispecific antibodies, today announced the closing of a USD 74 million Series B financing round. EpimAb secured funds from SDIC Fund, Sherpa Healthcare Partners and SCVC, 3E Bioventure Capital, Decheng Capital, Oriza Seed Capital and the Trend Investment Group. The company is deciding to use the funds to advance its bispecifics pipeline-based on its Fabs-in-Tandem Immunoglobin technology, abbreviated as Fit-IG. The company is also simultaneously working with U.K.-based Kymab and China’s Innovent and Teruisi, mainly in oncology based areas.
